in the development of hematopoietic malignancies. We report here the first demonstration of the effects of mutant p53 when introduced into normal murine bone marrow progenitor cells in vivo, namely the induction of hematopoietic disorders Introduction including myeloproliferative disease (MPD) and myelodysplastic syndrome (MDS). Tumorigenesis is generally accepted to be a multistep process involving the accumulation of genetic alterations of oncogenes and tumor suppressor genes. p53 mutations are the most common genetic alterations observed in human cancers Materials and methods including lymphomas and leukemias [1] [2] [3] and in many cancers, these mutations have been shown to inactivate the growthsuppressing activity of p53. 1, 3, 4 It has been shown that overRetrovirus production expression of mutant p53 results in development of a variety of tumors in transgenic mice, 5 transformation of normal cells The construction of the retroviral vector LK (vector alone in vitro in cooperation with activated ras, 6 and promotes the control) and Lp53Ac5 (containing a mutant p53 cDNA) was survival and proliferation of chronic myelogenous leukemia previously described. 17 The mutant p53 (p53 m ) virus producprogenitor cells in vitro. 7 The introduction of a mutant p53 ing cell line, p53Ac5 with a titer of 1 × 10 6 c.f.u./ml, and the allele into primary rat embryo fibroblasts containing an LK vector producing cell line, LK with a titer of 1 × 10 5 endogenous wild-type allele enhances the plating efficiency c.f.u./ml, were grown in Dulbecco's modified Eagle's medium of these cells, and their frequency of immortalization. 2 The (DMEM; Gibco, Gaithersburg, MD, USA) containing 10% dominant transforming effect of mutant p53 appears to be heat-inactivated fetal calf serum (FCS; Gibco). Once the cells mediated through the binding of wild-type p53 protein by had reached 80% confidence, DMEM was replaced by mutant p53 protein to form oligomeric protein complexes Iscove's modified Dulbecco's medium (IMDM; Cytosystems, thereby inactivating the function of wild-type p53. [8] [9] [10] [11] NSW, Australia) and retroviral supernatant was harvested 24 h Hematopoietic disorders result from disruption of the regulater followed by filtration with a 0.22 M low protein binding latory mechanisms that normally maintain steady-state hemafilter (Millipore, Bedford, MA, USA). The viral producers used topoiesis. 12, 13 Leukemia is characterized by the uncontrolled in this study were negative for the generation of replicationproliferation or expansion of hematopoietic cells that do not competent retroviruses (RCR) as determined by marker resretain the capacity to differentiate normally to mature blood cue assay.
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cells. 12,13 Certain hematopoietic disorders display part of the full leukemic phenotype -either growth expansion as seen in myeloproliferative disease (MPD) or differentiation block in the case of myelodysplastic syndrome (MDS), both of which 10% FCS, 8 g/ml polybrene (Sigma, St Louis, MO, USA), primers used in this study do not amplify endogenous p53 due to the specific design employed. 17 The RT-PCR products were 1 mg/ml bovine serum albumin (BSA; Sigma), 30 g/ml transferrin (Sigma), 10 ng/ml murine IL-6 (Genzyme, Cambridge, also probed with the same p53 probe as described above. MA, USA), 10 ng/ml murine stem cell factor (SCF; Genzyme), and 20% WEHI-3B cell-conditioned medium (WCM) as a source of IL-3. After this infection protocol, cells were washed in IMDM containing 2% FCS and resuspended in fresh IMDM were plated at 5 × 10 4 /ml in 0.8% methylcellulose medium 10 mM Tris HCl pH 8.3, 2.5 mM MgCl 2 , 0.1 mg/ml gelatin, supplemented with 25% horse serum (HS; Gibco), 50 units/ml 0.45% nonidet P40, 0.45% Tween 20) containing proteinase murine GM-CSF (Genzyme) for CFU-GM assay; 1% BSA K for 1 h at 55°C. Cellular RNA was isolated from both BM (Sigma), 10 −4 M 2-mercaptoethanol (Sigma), 200 units/ml and spleen cells derived from the same animals using guanidimurine IL-3 (Genzyme), 100 ng/ml IL-6 (Genzyme) and 2 nium thiocyanate.
21 Proviral integration was determined by units/ml erythropoietin (EPO, Sigma) for CFU-GEMM and PCR. This was performed by incubating DNA extraction with BFU-E assays. CFU-GM colonies were scored at day 7. CFU-40 pmoles of specific PCR primers for Lp53Ac5 provirus, 17 2 GEMM and BFU-E-derived colonies were scored on day 10-units of Taq polymerase (Perkin-Elmer, Foster City, CA, USA), 14 by morphological criteria and benzidine staining. Clono-0.25 mM dNTPs, 50 mM Tris HCl (pH 8.3) and 1 mM MgCl 2 .
genic progenitor content of bone marrow was evaluated as The thermal cycling program used was previously described. 17 total clonogenic progenitor number per femur. The PCR products (1.48 kb product of Lp53Ac5 provirus structure) were separated on a 1% agarose gel and then transferred to Hybond-N membranes (Amersham, Arlington Heights, IL, USA). The membranes were then probed with 32 Plabeled 1.3 kb BglII/SmaI p53 fragment. Proviral integration of Evaluation of cell viability the LK retrovirus in LK control mice was also determined by PCR using the primers specific for the region of MoMLV/MSV under the same conditions as described above.
Total cell number and cell viability in one femur from each sacrificed reconstituted animal were examined. Cell viability RNA samples were treated with RQ1 RNase-free DNase (Promega, Madison, WI, USA) at 37°C, for 30 min in 40 mM was determined by trypan blue exclusion. DNA fragmentation, a marker of apoptosis, was examined on paraffinTris HCl (pH 7.5), 10 mM NaCl and 2 mM MgCl 2 to remove residual DNA and then extracted with phenol/chloroform and embedded spleen tissue sections from one representative mouse of each myeloproliferative disease and MDS animals, precipitated. cDNA was synthesized from 1 g of the RNA samples in reaction mixture containing 50 mM Tris-HCl respectively, by terminal deoxynucleotidyl transferase (TdT) labeling of DNA breaks with biotin-labeled dUTP (Boehringer (pH 8.3), 50 mM KCl, 2.5 mM MgCl 2 , 10 mM DTT, 0.25 mM dNTPs, 1 units/ml RNasin (Promega), 100 units MMLV RTase Mannheim, Indianapolis, IN, USA) (TUNEL). 24 A spleen section prepared from a leukemic animal induced by v-myc (Promega) and 40 pmoles of 3Ј murine p53 primer. 17 Reactions were incubated at 37°C for 40 min, then 94°C for 3 min.
reconstitution was used as an apoptosis-positive control (Dolnikov et al; unpublished data). In negative controls the Control reactions were performed in the absence of added MMLV RTase. PCR reactions were then performed under the TdT was omitted. same conditions as those described above for DNA PCR. The Table 1 Disease The diagnosis is based on histopathologic examination of tissues,
Results
examination of blood smears and phenotypic analysis (morphology and cell surface markers) of bone marrow and spleen cells. b Latency is defined as the time-point when reconstituted mice
Experimental design
became moribund with disease symptoms of ruffled fur, inactivity, labored breathing and/or sudden loss of body weight. Mice were sacrificed immediately after they became ill.
In the present experiments, a single-gene retrovirus based on the LK vector 17 was used which contains mutant p53 cDNA (Lp53Ac5). This cDNA has a mutation at codon 135 that converts alanine to valine. Bone marrow from 8-week-old female BALB/c mice pretreated with 5-FU was incubated with in both bone marrow and spleen (Table 2) (Table 1 ). In addition, they exhibited pink of inactivity, weight loss, ruffled fur and labored breathing ( Table 1 ). The remaining three of these mice showed no disbone marrow and reduced size of thymus. Histopathology revealed excessive numbers of hematopoietic cells infiltrating ease symptoms with no detectable p53 m expression in the hematopoietic tissues when sacrificed at week 24 post-reconin the spleen, liver (for example mouse p53 m 4 in Figure 1 ) and lung (data not shown) to a far greater extent than those of stitution (data not shown). Twenty irradiated control animals, which received LK-infected post-5-FU bone marrow cells myeloproliferative disease animals and severely disrupting the normal tissue organization in the lung (data not shown), and remained healthy. Upon internal analysis, the diseased animals exhibited clear differences to the LK control or nonspleen and liver along with increased red pulp (Figure 1 ). In addition, unlike the myeloproliferative disorder mice, more p53 m -expressing animals. Histopathologic tissue examination and cell phenotypic analysis revealed two types of hematopoithan 60% of bone marrow content in these mice was replaced by erythrocytes ( Figure 1 ) with an increased number of abnoretic disorders, either a myeloproliferative disorder (MPD) or myelodysplastic syndrome (MDS). This characterization was mal megakaryocytes (data not shown) and substantially reduced numbers of mature cells of other lineages in the bone based on the severity of disease, in particular the degree of abnormal cell proliferation and differentiation, the affected marrow ( Figure 2 and Table 2 ). There was a significant increased frequency of erythroid cells in the BM (76.6 vs tissues and the proliferating cell types. MPD was characterized by abnormal extramedullary hematopoiesis in the 24.6% of LK) and spleen (25.9 vs 19.2% of LK) ( Table 2) , and a variation in the shape of erythrocytes (poikilocytosis) in the spleen, liver (Figure 1 ) lung and thymus (data not shown), and proliferation of abnormal numbers of immune hematopoietic BM (Figure 2 ) of MDS animals indicating a serious disturbance of erythropoiesis. These mice also exhibited reduced myeloid cells in the bone marrow (for example mouse p53 m 3 in Figure 1 ). In addition, phenotypic analysis also exhibited an and T lymphoid lineages in the spleen compared to LK control ( Table 2 ). Examination of blood smears was consistent with increased number of immature cells ( Figure 2 ) along with deceased number of myeloid lineage cells (Figure 2 and the above diagnosis of hematopoietic diseases that developed in the p53 m -reconstituted mice showing increased numbers Table 2 ), as well as decreased numbers of B lymphoid lineage All the LK-reconstituted mice showed normal histopathology as well as the normal constitution of cell types in the examined itssues (for example mouse LK2 in Figure 1 ). These were similar to the irradiated mice reconstituted with normal untreated bone marrow cells (data not shown).
Transduction and expression of p53 m in the hematopoietic tissues from affected mice of PCR products revealed the presence of proviral DNA (1.48 kb) in both bone marrow and spleen tissues from all the animals examined ( Figure 4 ). Southern blot analysis of RT-PCR of abnormal myelomonocytic cells in the MPD mice-derived blood ( Figure 3B ) and aberrant erythrocytes (poikilocytes) in products also revealed the expected 1.48 kb band, corresponding to the p53 m proviral structure. This was detectable the MDS mice-derived blood ( Figure 3C ), relative to LK mice ( Figure 3A) . No correlation was found between the latency in all the analyzed RNA samples extracted from BM and spleen tissues ( Figure 5 ), indicating p53 m gene expression in period and the disease type that developed (Table 1 ).
Figure 3
Morphology of peripheral blood cells in reconstituted mice. Blood smears were stained with May-Grünwald-Giemsa. Blood from control mouse LK3 shows normal erythrocytes and one neutrophilic granulocyte and mononuclear cell (a). Blood from p53 Bone marrow LK (n = 6) 30.4 ± 5.5 30.9 ± 6.5 17.6 ± 3. etic samples from both LK control and p53 m mice (data not shown), presumably due to the short half-life of wild-type p53 protein resulting in low levels of this protein by immunohistochemical assay. 3 However, by using PAb240 antibody variable numbers of positive cells with red brown staining in cytoplasm and nucleus were detectable in bone marrow assessment showed occasional apoptotic cells in the spleens (Figure 6a ) and spleen tissues (data not shown) derived from of representative mice from either MPD (p53 m 3) or MDS both p53 m MPD and MDS animals. PAb240-positive staining (p53 m 4) animals (data not shown). MDS mice exhibited a cells were rarely seen in the case of LK reconstituted mice slightly higher cell viability (88.8%) in BM compared to either (Figure 6a ). Mice with MDS had more p53 m protein-express-LK controls (83.6%) or MPD animals (82.8%). These results ing cells in both BM (37.4%) and spleen (19.6%) compared indicate that p53 m overexpression in hematopoietic tissues did to BM (18.0%) and spleen (13.0%) from MPD animals not affect apoptosis in the diseased animals. However, this (Figure 6b ). This indicates expression of p53 m protein in all the overexpression appeared to enhance BM cell viability at ceraffected animals and an apparent correlation of the number of tain stages in the affected animals thereby resulting in a more p53 m -expressing cells with the degree of severity of the hemasevere hematopoietic disease. Clonogenic assays demontopoietic disorders in the p53 m reconstituted animals. The strated that compared to the LK control, bone marrow derived background immunoreactivity of LK and p53 m samples with from p53 m mice with MPD had a higher colony forming IgG1 murine polyclonal antibody was negligible (data not ability for the examined progenitors containing 1.82-fold more shown).
multilineage clonogenic progenitors (CFU-GEMM), 1.35-fold more myeloid clonogenic progenitors (CFU-GM) and 1.37-fold more erythroid clonogenic progenitors (BFU-E) (Table 3) . However, unlike MPD animals, relative to LK mice, animals
Effects of overexpression of p53 m on the proliferation with MDS exhibited a reduced colony-forming ability for the and cell viability of hematopoietic cells in vivo examined progenitors with decreased levels of CFU-GEMM (3.8-fold), CFU-GM (4.4-fold) and BFU-E (2.6-fold) in bone To assess the effects of p53 m overexpression on hematopoietic marrow (Table 3) . Taken together, the results indicate that cells in vivo, cell viability and clonogenic progenitor content overexpression of p53 m can affect proliferation and survival in bone marrow were examined for each sacrificed animal.
of BM clonogenic progenitors in vivo apparently thereby No significant difference of average cellularity per femur resulting in abnormal hematopoiesis. between LK and p53 m reconstituted animals was found (data not shown). In addition, similar to LK control mice, TUNEL . 17 The numbers of hematopoietic progenitors in the BM cytochemical analysis in hematopoietic tissues of these affected mice. This is probably due to mutant p53 protein accumuof MDS mice were significantly reduced relative to LK mice indicating a suppression of proliferative capacity of lation in cells due, at least in part, to its increased half-life, allowing immunocytochemical detection.
22, 26 The number of hematopoietic progenitor cells in these mice. Together with the different number of p53 m expressing cells detected in p53 m -expressing cells detected by immunocytochemistry appears to be consistent with the degree of severity of the hematopoietic tissues of MPD and MDS mice, the finding of decreased progenitors in MDS mice suggests that the prohematopoietic disease that developed, indicating an association of the overall level of p53 m in hematopoietic cells with portion of p53 m expressing cells in the hematopoietic system may affect the proliferative ability of the hematopoietic prothe type of hematopoietic disorder. This is the first demonstration of the effects of constitutive genitor cells. In addition, the finding of the disturbed maturation of hematopoietic cells in these diseased mice indicates expression of mutant p53 when specifically introduced into hematopoietic cells in vivo. The results show that this enginan effect of p53 m on lineage commitment and terminal differentiation. Therefore, the consequent abnormal hematopoietic eered overexpression of p53 m caused development of MPD and MDS. There were some similarities in the symptoms and proliferation and differentiation appears to contribute to the development of the hematopoietic disorders. phenotypes with respect to the sites of pathology: lung, liver, thymus, spleen and BM in both MPD and MDS animals. HowMutation of the p53 gene has been reported as having a dominant-negative mode of action on the remaining wild-type ever, the MDS condition was more severe in terms of the extent and nature of the pathology exhibited, decreased proallele, 10 ,30 the p53 m protein being able to complex with wildtype protein and thereby inhibiting its action. 8 This leads to liferative capability of clonogenic progenitors in BM, and abnormal erythropoiesis. p53 mutations have been detected loss of DNA binding of the wild-type protein 30-32 and reduced transactivation activity. 9, [33] [34] [35] [36] We, therefore, hypothesize that in many hematopoietic malignancies including acute myelogenous leukemia (AML), chronic myelogenous leukemia introduction of p53 m in the present study mimics loss or mutation of one or two (depending on the level of mutant p53 (CML) and myelodysplastic syndrome (MDS), and the progression of the hematopoietic malignancies is often associated expression), wild-type alleles and may thus induce hematopoietic malignancies by a negative dominant inhibiwith these mutations. 3 It has been shown that mutations of p53 occur in the subtypes of MDS with a poor prognosis as tory effect of p53 m on the function of endogenous wild-type p53. [8] [9] [10] Distinct p53 gene abnormalities (p53 allele loss, p53 classified by the French-American-British (FAB) classification. 27, 28 In addition, evolution of CML and MDS to mutation, or both) may cause different degrees of p53 inactivation, exert different tumorigenic potentials and thus play difmyeloid blast crisis and AML, respectively, has been associated with loss of one of the short arms of chromosome 17 (17p, ferent roles during multistage of tumorigenesis. 37 The finding of an association of the proportion of p53 m -expressing hemacontaining p53) and mutations on the remaining p53 allele. 3 The development of hematopoietic disease in p53 m reconstitopoietic cells with the type of hematopoietic disorders may relate to the degree of p53 m inactivation of wild-type p53 in tuted mice shown here is consistent with previous observations: (1) that introduction of the same p53 m into normal these cells leading to different stages of preleukemia development, namely MPD and MDS. This hypothesis is supported by murine hematopoietic cells in vitro resulted in enhanced pro-
